Antipsychotics activate mTORC1-dependent translation to enhance neuronal morphological complexity

Science Signaling

Volumn 7, Issue 308, 2014, Pages

  Bowling, Heather ^a   Zhang, Guoan ^a   Bhattacharya, Aditi ^b   Pérez Cuesta, Luis M ^a   Deinhardt, Katrin ^a,c   Hoeffer, Charles A ^a,d   Neubert, Thomas A ^a   Gan, Wen Biao ^a   Klann, Eric ^b   Chao, Moses V ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY   (United States)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^d UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSKELETON PROTEIN; HALOPERIDOL; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; PROTEIN KINASE B; PROTEIN S6;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BRAIN CELL; CELL STRUCTURE; CONTROLLED STUDY; IN VIVO STUDY; MALE; MASS SPECTROMETRY; MOUSE; NERVE CELL; NERVE CELL CULTURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; PROTEOMICS; PYRAMIDAL NERVE CELL; SIGNAL TRANSDUCTION;

ANIMALS; ANTIPSYCHOTIC AGENTS; CELLS, CULTURED; HALOPERIDOL; MICE; MICE, INBRED C57BL; MULTIPROTEIN COMPLEXES; NEURONS; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84892633789     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.2004331     Document Type: Article

References (61)

1. J. A. Lieberman, T. S. Stroup, J. P. McEvoy, M. S. Swartz, R. A. Rosenheck, D. O. Perkins, R. S. Keefe, S. M. Davis, C. E. Davis, B. D. Lebowitz, J. Severe, J. K. Hsaio; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators, Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353, 1209-1223 (2005).
2. S. Kapur, T. Arenovich, O. Agid, R. Zipursky, S. Lindborg, B. Jones, Evidence for onset of antipsychotic effects within the first 24 hours of treatment. Am. J. Psychiatry 162, 939-946 (2005).
3. P. Wright, S. R. Lindborg, M. Birkett, K. Meehan, B. Jones, K. Alaka, I. Ferchland-Howe, A. Pickard, C. C. Taylor, J. Roth, J. Battaglia, I. Bitter, G. Chouinard, P. L. Morris, A. Breier, Intramuscular olanzapine and intramuscular haloperidol in acute schizophrenia: Antipsychotic efficacy and extrapyramidal safety during the first 24 hours of treatment. Can. J. Psychiatry 48, 716-721 (2003).
4. J. Volavka, T. B. Cooper, P. Czobor, M. Meisner, Plasma haloperidol levels and clinical effects in schizophrenia and schizoaffective disorder. Arch. Gen. Psychiatry 52, 837-845 (1995).
5. B. S. Bunney, Antipsychotic drug effects on the electrical activity of dopaminergic neurons. Trends Neurosci. 7, 212-215 (1984).
6. E. S. Emamian, D. Hall, M. J. Birnbaum, M. Karayiorgou, J. A. Gogos, Convergent evidence for impaired AKT1-GSK3b signaling in schizophrenia. Nat. Genet. 36, 131-137 (2004).
7. T. Del'Guidice, M. Lemasson, J. M. Beaulieu, Role of beta-arrestin 2 downstream of dopamine receptors in the basal ganglia. Front. Neuroanat. 5, 58 (2011).
8. R. S. Jope, M. S. Roh, Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions. Curr. Drug Targets 7, 1421-1434 (2006).
9. S. Leucht, W. Kissling, J. McGrath, Lithium for schizophrenia. Cochrane Database Syst. Rev. CD003834 3 (2007).
10. C. E. Holt, E. M. Schuman, The central dogma decentralized: New perspectives on RNA function and local translation in neurons. Neuron 80, 648-657 (2013).
11. M. D. Antion, M. Merhav, C. A. Hoeffer, G. Reis, S. C. Kozma, G. Thomas, E.M. Schuman, K. Rosenblum, E. Klann, Removal of S6K1 and S6K2 leads to divergent alterations in learning, memory, and synaptic plasticity. Learn. Mem. 15, 29-38 (2008).
12. C. A. Hoeffer, K. K. Cowansage, E. C. Arnold, J. L. Banko, N. J. Moerke, R. Rodriguez, E. K. Schmidt, R. E. Lloyd, P. Pierre, G. Wagner, J. E. LeDoux, E. Klann, Inhibition of the interactions between eukaryotic initiation factors 4E and 4G impairs long-term associative memory consolidation but not reconsolidation. Proc. Natl. Acad. Sci. U.S.A. 108, 3383-3388 (2011).
13. A. Bhattacharya, H. Kaphzan, A. C. Alvarez-Dieppa, J. P. Murphy, P. Pierre, E. Klann, Genetic removal of p70 S6 kinase 1 corrects molecular, synaptic, and behavioral phenotypes in fragile X syndrome mice. Neuron 76, 325-337 (2012).
14. E. Santini, E. Klann, Dysregulated mTORC1-dependent translational control: From brain disorders to psychoactive drugs. Front. Behav. Neurosci. 5, 76 (2011).
15. O. Meyuhas, Physiological roles of ribosomal protein S6: One of its kind. Int. Rev. Cell Mol. Biol. 268, 1-37 (2008).
16. I. Ruvinsky, O. Meyuhas, Ribosomal protein S6 phosphorylation: From protein synthesis to cell size. Trends Biochem. Sci. 31, 342-348 (2006).
17. 3 dopamine receptors in vivo. J. Neurosci. 27, 881-885 (2007).
18. 2 receptor-expressing striatal neurons in response to cocaine and haloperidol. J. Neurosci. 28, 5671-5685 (2008).
19. L. Donnelly, P. S. Waraich, C. E. Adams, K. M. Hamill, J. Marti, M. Roque I Figuls, J. Rathbone, Haloperidol dose for the acute phase of schizophrenia. Cochrane Database Syst. Rev. CD001951 (2010).
20. P. Seeman, T. Lee, Antipsychotic drugs: Direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 188, 1217-1219 (1975).
21. T. Okuzumi, D. Fiedler, C. Zhang, D. C. Gray, B. Aizenstein, R. Hoffman, K. M. Shokat, Inhibitor hijacking of Akt activation. Nat. Chem. Biol. 5, 484-493 (2009).
22. E. Santini, T. N. Huynh, A. F. MacAskill, A. G. Carter, P. Pierre, D. Ruggero, H. Kaphzan, E. Klann, Exaggerated translation causes synaptic and behavioural aberrations associated with autism. Nature 493, 411-415 (2013).
23. E. K. Schmidt, G. Clavarino, M. Ceppi, P. Pierre, SUnSET, a nonradioactive method to monitor protein synthesis. Nat. Methods 6, 275-277 (2009).
24. M. Kobayashi, A. C. Wilson, M. V. Chao, I. Mohr, Control of viral latency in neurons by axonal mTOR signaling and the 4E-BP translation repressor. Genes Dev. 26, 1527-1532 (2012).
25. L. R. Pearce, G. R. Alton, D. T. Richter, J. C. Kath, L. Lingardo, J. Chapman, C. Hwang, D. R. Alessi, Characterization of PF-4708671, a novel and highly specific inhibitor of p70 ribosomal S6 kinase (S6K1). Biochem. J. 431, 245-255 (2010).
26. C. C. Thoreen, L. Chantranupong, H. R. Keys, T. N. S. Wang Gray, D. M. Sabatini, A unifying model for mTORC1-mediated regulation of mRNA translation. Nature 485, 109-113 (2012).
27. D. Ma, M. K. Chan, H. E. Lockstone, S. R. Pietsch, D. N. Jones, J. Cilia, M. D. Hill, M. J. Robbins, I. M. Benzel, Y. Umrania, P. C. Guest, Y. Levin, P. R. Maycox, S. Bahn, Antipsychotic treatment alters protein expression associated with presynaptic function and nervous system development in rat frontal cortex. J. Proteome Res. 8, 3284-3297 (2009).
28. M. K. Chan, T. M. Tsang, L. W. Harris, P. C. Guest, E. Holmes, S. Bahn, Evidence for disease and antipsychotic medication effects in post-mortem brain from schizophrenia patients. Mol. Psychiatry 16, 1189-1202 (2011).
29. D. S. Spellman, K. Deinhardt, C. C. Darie, M. V. Chao, T. A. Neubert, Stable isotopic labeling by amino acids in cultured primary neurons: Application to brain-derived neurotrophic factor-dependent phosphotyrosine-associated signaling. Mol. Cell. Proteomics 7, 1067-1076 (2008).
30. M. T. Butko, J. N. Savas, B. Friedman, C. Delahunty, F. Ebner, J. R. Yates III, R. Y. Tsien, In vivo quantitative proteomics of somatosensory cortical synapses shows which protein levels are modulated by sensory deprivation. Proc. Natl. Acad. Sci. U.S.A. 110, E726-E735 (2013).
31. J. J. Hodas, A. Nehring, N. Höche, M. J. Sweredoski, R. Pielot, S. Hess, D. A. Tirrell, D. C. Dieterich, E. M. Schuman, Dopaminergic modulation of the hippocampal neuropil proteome identified by bioorthogonal noncanonical amino acid tagging (BONCAT). Proteomics 12, 2464-2476 (2012).
32. A. Harada, J. Teng, Y. Takei, K. Oguchi, N. Hirokawa, MAP2 is required for dendrite elongation, PKA anchoring in dendrites, and proper PKA signal transduction. J. Cell Biol. 158, 541-549 (2002).
33. Y. Chen, W. Y. Fu, J. P. Ip, T. Ye, A. K. Fu, M. V. Chao, N. Y. Ip, Ankyrin repeat-rich membrane spanning protein (kidins220) is required for neurotrophin and ephrin receptor-dependent dendrite development. J. Neurosci. 32, 8263-8269 (2012).
34. S. H. Wu, J. C. Arévalo, F. Sarti, L. Tessarollo, W. B. Gan, M. V. Chao, Ankyrin repeatrich membrane spanning/Kidins220 protein regulates dendritic branching and spine stability in vivo. Dev. Neurobiol. 69, 547-557 (2009).
35. V. E. Neubrand, F. Cesca, F. Benfenati, G. Schiavo, Kidins220/ARMS as a functional mediator of multiple receptor signalling pathways. J. Cell Sci. 125, 1845-1854 (2012).
36. Ensembl Genome Browser; http://www.ensembl.org/.
37. R. D. Penrod, S. Kourrich, E. Kearney, M. J. Thomas, L. M. Lanier, An embryonic culture system for the investigation of striatal medium spiny neuron dendritic spine development and plasticity. J. Neurosci. Methods 200, 1-13 (2011).
38. K. R. Williams, H. C. Hemmings Jr., M. B. LoPresti, W. H. Konigsberg, P. Greengard, DARPP-32, a dopamine- and cyclic AMP-regulated neuronal phosphoprotein. Primary structure and homology with protein phosphatase inhibitor-1. J. Biol. Chem. 61, 1890-1903 (1986).
39. T. A. Ferreira, L. L. Iacono, C. T. Gross, Serotonin receptor 1A modulates actin dynamics and restricts dendritic growth in hippocampal neurons. Eur. J. Neurosci. 32, 18-26 (2010).
40. G. Yang, F. Pan, P. C. Chang, F. Gooden, W. B. Gan, Transcranial two-photon imaging of synaptic structures in the cortex of awake head-restrained mice. Methods Mol. Biol. 1010, 35-43 (2013).
41. Allen Brain Atlas; http://www.brain-map.org/.
42. 125I]iodosulpride. Neuroscience 20, 117-155 (1987).
43. P. S. Goldman-Rakic, Topography of cognition: Parallel distributed networks in primate association cortex. Annu. Rev. Neurosci. 11, 137-156 (1988).
44. E. Valjent, J. Bertran-Gonzalez, H. Bowling, S. Lopez, E. Santini, M. Matamales, A. Bonito-Oliva, D. Hervé, C. Hoeffer, E. Klann, J. A. Girault, G. Fisone, Haloperidol regulates the state of phosphorylation of ribosomal protein S6 via activation of PKA and phosphorylation of DARPP-32. Neuropsychopharmacology 36, 2561-2570 (2011).
45. A. Bonito-Oliva, S. Pallottino, J. Bertran-Gonzalez, J. A. Girault, E. Valjent, G. Fisone, Haloperidol promotes mTORC1-dependent phosphorylation of ribosomal protein S6 via dopamine- and cAMP-regulated phosphoprotein of 32 kDa and inhibition of protein phosphatase-1. Neuropharmacology 72, 197-203 (2013).
46. D. Silvera, S. C. Formenti, R. J. Schneider, Translational control in cancer. Nat. Rev. Cancer 10, 254-266 (2010).
47. A. J. Law, L. J. Hutchinson, P. W. Burnet, P. J. Harrison, Antipsychotics increase microtubule-associated protein 2 mRNA but not spinophilin mRNA in rat hippocampus and cortex. J. Neurosci. Res. 76, 376-382 (2004).
48. M. S. Lidow, Z. M. Song, S. A. Castner, P. B. Allen, P. Greengard, P. S. Goldman-Rakic, Antipsychotic treatment induces alterations in dendrite- and spine-associated proteins in dopamine-rich areas of the primate cerebral cortex. Biol. Psychiatry 49, 1-12 (2001).
49. S. Navari, P. Dazzan, Do antipsychotic drugs affect brain structure? A systematic and critical review of MRI findings. Psychol. Med. 39, 1763-1777 (2009).
50. S. W. Park, C. H. Lee, H. Y. Cho, M. K. Seo, J. G. Lee, B. J. Lee, W. Seol, B. S. Kee, Y. H. Kim, Effects of antipsychotic drugs on the expression of synaptic proteins and dendritic outgrowth in hippocampal neuronal cultures. Synapse 67, 224-234 (2013).
51. F. M. Benes, P. A. Paskevich, V. B. Domesick, Haloperidol-induced plasticity of axon terminals in rat substantia nigra. Science 221, 969-971 (1983).
52. G. E. Meredith, I. E. De Souza, T. M. Hyde, G. Tipper, M. L. Wong, M. F. Egan, Persistent alterations in dendrites, spines, and dynorphinergic synapses in the nucleus accumbens shell of rats with neuroleptic-induced dyskinesias. J. Neurosci. 20, 7798-7806 (2000).
53. L. A. Glantz, D. A. Lewis, Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. Arch. Gen. Psychiatry 57, 65-73 (2000).
54. P. Kreczmanski, H. Heinsen, V. Mantua, F. Woltersdorf, T. Masson, N. Ulfig, R. Schmidt-Kastne, H. Korr, H. W. Steinbusch, P. R. Hof, C. Schmitz, Volume, neuron density and total neuron number in five subcortical regions in schizophrenia. Brain 130 (Pt. 3), 678-692 (2007).
55. B. C. Ho, N. C. Andreasen, S. Ziebell, R. Pierson, V. Magnotta, Long-term antipsychotic treatment and brain volumes: A longitudinal study of first-episode schizophrenia. Arch. Gen. Psychiatry 68, 128-137 (2011).
56. A. C. Vernon, S. Natesan, M. Modo, S. Kapur, Effect of chronic antipsychotic treatment on brain structure: A serial magnetic resonance imaging study with ex vivo and postmortem confirmation. Biol. Psychiatry 69, 936-944 (2011).
57. N. L. Hutcheson, D. G. Clark, M. S. Bolding, D. M. White, Basal ganglia volume in unmedicated patients with schizophrenia is associated with treatment response to antipsychotic medication. Psychiatry Res. 10.1016/j.pscychresns. 2013.10.002 (2013).
58. G. Okugawa, K. Nobuhara, K. Takase, Y. Saito, M. Yoshimura, T. Kinoshita, Olanzapine increases grey and white matter volumes in the caudate nucleus of patients with schizophrenia. Neuropsychobiology 55, 43-46 (2007).
59. K. Deinhardt, T. Kim, D. S. Spellman, R. E. Mains, B. A. Eipper, T. A. Neubert, M. V. Chao, B. L. Hempstead, Neuronal growth cone retraction relies on proneurotrophin receptor signaling through Rac. Sci. Signal. 4, ra82 (2011).
60. E. Bálint, T. Kitka, G. Zachar, A. Adám, H. C. Hemmings Jr., A. Csillag, Abundance and location of DARPP-32 in striato-tegmental circuits of domestic chicks. J. Chem. Neuroanat. 28, 27-36 (2004).
61. C. C. Ouimet, P. Greengard, Distribution of DARPP-32 in the basal ganglia: An electron microscopic study. J. Neurocytol. 19, 39-52 (1990).